Systemic glucocorticoid use in Denmark: a population-based prevalence study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Glucocorticoid (GC) use is widespread and associated with many adverse effects. Thus, it is important to ascertain GC utilisation patterns. In this study, we examined the annual prevalence of prescription users and amount of use of systemic GCs. DESIGN: Population-wide prevalence study. SETTING: The primary healthcare and hospital sectors in Denmark from 1999 to 2015. RESULTS: Approximately 3% of the Danish population redeemed at least one prescription for a systemic GC annually between 1999 and 2015, with annual prevalence remaining constant over the period. However, after adjusting for age and sex, we observed a decrease in annual prevalence from 1999 to 2015, with a prevalence ratio of 0.92 (95% CI 0.91 to 0.92). Annual prevalence was highest among the elderly (7.0%-8.2% among persons 65-79 years of age and 8.4%-10% among persons 80+ years of age). Prednisolone was the most frequently redeemed systemic GC, with annual prevalence increasing from 1.4% to 2.1% during the 1999-2015 period. The amount of systemic GCs provided to the hospital sector increased from 2.3 defined daily doses (DDD)/1000 inhabitants/day in 1999 to 3.5 DDD/1000 inhabitants/day in 2015, while the amount provided to the primary healthcare sector remained constant in the range of 10-11 DDD/1000 inhabitants/day. CONCLUSION: We found a high prevalence of systemic GC use of 3% with a remarkably high prevalence in elderly of up to 10%, wherefore continued awareness of its effects is mandated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a population-based study from Denmark, the annual prevalence of systemic glucocorticoid prescription in primary care was found to be 3% with a remarkably high rate among the elderly of up to 10% during 1999-2015 (7).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Danish Civil Registration System
Pedersen, C. B. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810387965 · Cited by 4,632
The Danish National Prescription Registry
Wallach Kildemoes, H., Toft Sørensen, H., & Hallas, J. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810394717 · Cited by 2,467
Self-citationThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · cited 1×
“8 They also are associated with increased risk of osteoporosis 9 and neuropsychiatric disorders.”
BackgroundUse of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Glucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
Johannesdottir, S. A., Horváth-Puhó, E., Dekkers, O. M., Cannegieter, S. C., Jørgensen, J. O. L., Ehrenstein, V., Vandenbroucke, J. P., Pedersen, L., & Sørensen, H. T. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.122 · Cited by 465
Self-citationAdrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Self-citationPrevalence of oral glucocorticoid usage in the United States: a general population perspective
Overman, R. A., Yeh, J., & Deal, C. L. (2013) · Arthritis Care & Research · doi:10.1002/acr.21796 · Cited by 405 · cited 1×
“7%)).(13) The high prevalence of GC use observed among the elderly in our study is noteworthy, as it is well established that persons in the highest age groups are particularly prone to adverse outcomes due to higher levels of comorbidity, senescent changes in the body composition and polypharmacy.”
BackgroundPrevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Fardet, L., Petersen, I., & Nazareth, I. (2011) · Rheumatology · doi:10.1093/rheumatology/ker017 · Cited by 319
Self-citationFardet, L., Petersen, I., & Nazareth, I. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11071009 · Cited by 287 · cited 1×
“They also are associated with increased risk of osteoporosis(9) and neuropsychiatric disorders.(10) Current knowledge of GC utilisation patterns is in need of updating and expansion.”
BackgroundSelf-citationGlucocorticoids and cardiovascular events in rheumatoid arthritis: A population‐based cohort study
Davis, J. M., Maradit Kremers, H., Crowson, C. S., Nicola, P. J., Ballman, K. V., Therneau, T. M., Roger, V. L., & Gabriel, S. E. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22418 · Cited by 233
Principles of Drug Therapy for the Elderly Patient
Bressler, R., & Bahl, J. J. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.12.1564 · Cited by 205
Minichiello, É., Semerano, L., & Boissier, M. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2016.07.007 · Cited by 159
Christiansen, C. F. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.297 · Cited by 120
Fardet, L., Petersen, I., & Nazareth, I. (2012) · BMJ · doi:10.1136/bmj.e4928 · Cited by 116
Self-citationThe effects of prednisone therapy on plasma lipoproteins and apolipoproteins: A prospective study
Zimmerman, J., FAINARU, M., & Eisenberg, S. (1984) · Metabolism · doi:10.1016/0026-0495(84)90006-4 · Cited by 115
Hammer, T., Nielsen, K. R., Munkholm, P., Burisch, J., & Lynge, E. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw050 · Cited by 85
Simpson, C. R., Hippisley‐Cox, J., & Sheikh, A. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x514729 · Cited by 65
Cited by
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Metadata
- Authors
- Laugesen, K., Jørgensen, J. O. L., Sørensen, H. T., & Petersen, I.
- Affiliations
- Aarhus University Hospital (DK)
- Corresponding author
- Laugesen, Kristina
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-05
- Volume
- 7
- Issue
- 5
- Pages
- e015237
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5729989
- OpenAlex
- W2617455127
- Cited by
- 61
- References
- 18
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 7 · 2019: 10 · 2018: 4 · 2017: 2
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Program for Clinical Research Infrastructure
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- systemic glucocorticoids, prednisolone, defined daily doses, older adults, primary care, hospital prescribing, Denmark
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cross-Sectional Studies, Denmark, Drug Utilization, Female, Glucocorticoids, Humans, Infant, Infant, Newborn, Male, Middle Aged, Drug Prescriptions, Registries, Regression Analysis, Multivariate Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.